EP2244686A1 - Procédé et dispositif pour remplir des gélules - Google Patents

Procédé et dispositif pour remplir des gélules

Info

Publication number
EP2244686A1
EP2244686A1 EP09708924A EP09708924A EP2244686A1 EP 2244686 A1 EP2244686 A1 EP 2244686A1 EP 09708924 A EP09708924 A EP 09708924A EP 09708924 A EP09708924 A EP 09708924A EP 2244686 A1 EP2244686 A1 EP 2244686A1
Authority
EP
European Patent Office
Prior art keywords
capsule
amino
quinazoline
phenyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09708924A
Other languages
German (de)
English (en)
Inventor
Michael Spallek
Burkhard Metzger
Rolf Kuhn
Stefan Lustenberger
Hubert Hoelz
Torsten Kuehn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to EP09708924A priority Critical patent/EP2244686A1/fr
Publication of EP2244686A1 publication Critical patent/EP2244686A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations

Definitions

  • the invention relates to a method for filling a capsule with a pharmaceutical active ingredient formulation, wherein the capsule consists of two capsule parts (a capsule body and a capsule cap) and the two capsule parts telescopically without pre-locking in the unfilled state only after filling a capsule part with a pharmaceutical drug formulation be plugged together, as well as a device to do so.
  • Capsules with pharmaceutical preparations are widely used in the therapy and diagnosis of diseases.
  • the capsules may be administered orally or used in certain medical devices such as powder inhalers.
  • a capsule consists of two parts, namely a capsule body and a capsule cap, which are telescoped into one another.
  • the parts of the capsules are often made of gelatin, in particular hard gelatin, or of HPMC (hydroxypropylmethylcellulose).
  • HPMC hydroxypropylmethylcellulose
  • the parts of the capsules also consist of human-digestible, water-soluble plastics to release, for example, when administered orally, the active ingredient in certain compartments of the gastrointestinal tract.
  • EP 1 100 474 B1 discloses plastic capsules which are made of a capsule body and a capsule cap, both made of the same non-water-soluble, hydrophobic plastic material and connected to one another in such a way that a stable, closed cavity of defined volume is formed.
  • the plastic is polyethylene.
  • the capsules are intended for use in powder inhalers. As an example of such powder inhalers may be mentioned: HandiHaler ® , as he z. B.
  • DE 10 2005 001 332 A1 describes a two-part capsule with a complex geometry which allows a prefastening.
  • the two parts of the capsule are each made separately and pushed together in a releasable pre-locking position to prevent the ingress of foreign particles into the capsule before it is filled.
  • the pre-locking position in the capsule parts can consist of different structures in the capsule walls: for example, knobs or annular beads, which respectively engage in the depressions on the other capsule half.
  • capsules which have neither a preload position in the capsule body nor in the cap can also be stored in a pre-rest position. be brought to rest position. These capsules are then simply telescoped together before filling.
  • the pre-locked capsules with or without pre-locking position, are delivered to the bottler and placed in a filling device. After aligning the capsules in the device for filling the capsule body are non-destructively separated from the capsule caps. The separation can take place without disturbing the filling process only with the required speed, if a pre-locking force, ie the effective force between the capsule body and the capsule cap in the pre-locking position, is exactly adhered to, which is accompanied by the maintenance of small manufacturing tolerances in the manufacturing process.
  • a pre-locking force ie the effective force between the capsule body and the capsule cap in the pre-locking position
  • the pharmaceutical active substance formulation for example in the form of powder, pellets and / or microtablets, is introduced into the capsule body. Subsequently, the capsule body and the capsule cap are telescoped together and brought into a closed position. The force required to reach the locking position is greater than the pre-locking force.
  • the object is achieved in the method in that the capsule body and the capsule caps are placed separately in a device for filling, without first to lock the two capsule halves and separate again before filling each other.
  • the method achieves simple process control with reduced fine-tuning of the handling devices and handling forces during filling.
  • the cylindrical capsules have only one latching position (final latching position), which is defined in particular by a circumferential groove and a bead corresponding thereto.
  • final latching position which is defined in particular by a circumferential groove and a bead corresponding thereto.
  • This is accompanied by a simplified production and handling of the capsule body and the capsule caps.
  • the handling is simplified both in the manufacturer of the capsule body and capsule caps as well as in the bottler of the drug formulation.
  • the capsule manufacturer saves the formation of a Vorrastpositi- on in the two capsule parts and the Vorverrasten the two capsule parts during capsule production.
  • the filler saves the separation of the two capsule halves before filling. In total, 3 working steps are saved.
  • the capsule bodies and capsule caps of the lockable capsules consist of all conventional materials known to the person skilled in the art, in particular of injection-molded polymer material.
  • the capsules can serve any application form; They are designed especially for use in the above-mentioned inhalers and most preferably for the Handi- Haler ® as disclosed in EP 1,342,483th
  • capsule bodies and capsule caps are made, for example, from PP, PE or ABS and have an modulus of elasticity in the range from 200 to 3600 MPa, in particular in the range from 400 to 3000 MPa, the resulting stability leads to a disruption of the filling process leading deformation of the capsule body or capsule caps avoided.
  • An e-module Range between 600 and 1400 MPa has proven to be particularly advantageous.
  • the capsule elements are treated by means of ionizing gases after their preparation, electrostatic charges of the capsule bodies and, consequently, a particle load can be further reduced.
  • the separately present capsule cap and body can be easily subjected to a drying process or a flooding with dry gases, whereby a complete drying of the inner surface of the two capsule parts is ensured. This drying is required for the storage of the capsules and simplifies the filling of powdered drug formulations.
  • the capsule body and the capsule caps can be visually inspected immediately before filling. This can be done for example by means of image acquisition and processing systems automatically or by the operator. Thus, damage to or in the capsule parts can be detected early before filling and drug safety can be increased.
  • the object is achieved in a device for filling capsules with pharmaceutical active ingredient formulations for carrying out the method according to the invention in that the capsule delivery device receiving cavities for separate recording of capsule bodies and capsule caps and separate reservoir for capsule body and capsule caps has.
  • a Kapselabhelillvorraum is characterized by a simplified design and allows, compared to a filling device known from the prior art, to achieve an increased process speed, since no Vorverrastung the capsules to solve before filling.
  • the capsules can be filled with medicines of any kind.
  • the filling with medicaments takes place in powder form.
  • W is a pharmacologically active agent and (for example) selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HIV antihistaminics, PAF antagonists and PI3 kinase inhibitors.
  • a pharmacologically active agent selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HIV antihistaminics, PAF antagonists and PI3 kinase inhibitors.
  • two- or three-fold combinations of W can be combined and used for application in the device according to the invention. Exemplary combinations of W would be:
  • W represents a betamimetics combined with an anticholinergic, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists,
  • W represents an anticholinergic, combined with a betamimetics, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists,
  • W represents a corticosteroid combined with a PDE4 inhibitor, EGFR inhibitor or LTD4 antagonist W represents a PDE4 inhibitor combined with an EGFR inhibitor or LTD4 antagonist
  • W represents an EGFR inhibitor combined with a LTD4 antagonist.
  • Preferred betamimetics for this purpose are compounds selected from the group consisting of albuterol, arformoterol, bambuterol, bitolterol, broxeterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharines, isoprenaline, levosalbutamol, mabuterol , Meluadrine, Metaproterenol, Orciprenaline, Pirbuterol, Procaterol, Reproterol, Rimiterol, Ritodrine, Salmefamol, Salmeterol, Soterenol, Sulphone terol, Terbutaline, Tiaramide, Tolubuterol, Zinterol, CHF-1035, HOKU-81, KUL-1248 and 3- (4- ⁇ 6- [2-hydroxy-2- (4-hydroxy-3-hydroxymethylphenyl) ethylamino] -hexyloxy ⁇
  • the acid addition salts of the betamimetics are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydroxides citrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Preferred anticholinergic compounds are compounds which are selected from the group consisting of tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts , preferably the chloride salt, tolterodine.
  • the cations are the pharmacologically active ingredients.
  • the abovementioned salts may preferably contain chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate , Succinate, benzoate or p-toluenesulfonate, with chloride, bromide, iodide, sulfate, methanesulfonate or p-toluenesulfonate being preferred as counterions.
  • the chlorides, bromides, iodides and methanesulfonates are particularly preferred.
  • anticholinergics are selected from the salts of the formula AC-I
  • X - is a single negatively charged anion, preferably one Anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulfonate, preferably a single negatively charged anion, particularly preferably an anion selected from the group consisting of fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, particularly preferably bromide, if appropriate in the form of their racemates, enantiomers or hydrates.
  • Anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, a
  • X - may have the meanings given above.
  • Further preferred anticholinergics are selected from the salts of the formula AC-2
  • the compound of formula AC-2 may also be in the form of the free base AC-2-base.
  • Preferred corticosteroids are compounds selected from the group consisting of beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone, RPR -106541, NS-126, ST-26 and 6,9-Difluoro-17- [(2-furanylcarbonyl) oxy] -ll-hydroxy-16-methyl-3-oxo-androsta-1,4-diene-17-carbothionic acid (S) -fluoromethyl ester
  • any reference to steroids includes reference to their optional salts or derivatives, hydrates or solvates.
  • Examples of possible salts and derivatives of steroids may be: alkali metal salts, such as, for example, sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates.
  • Preferred PDE4 inhibitors used here are compounds selected from the group consisting of enprofylline, theophylline, roflumilast, ariflo (cillobast), tofimilast, pumafentrin, lirimilast, arofylline, atizoram, D-4418 198004, BY343, CP-325,366, D-4396 (Sch351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T- 2585, V-11294A, Cl-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and
  • the acid addition salts of the PDE4 inhibitors are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro p-toluenesulfonate.
  • Preferred LTD4 antagonists here are compounds selected from the group consisting of montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078 , VUF-K-8707, L-733321 and
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofluorate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • salts or derivatives which the LTD4-antagonists are capable of forming include: alkali metal salts, such as, for example, sodium or potassium salts, alkaline earth salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates ,
  • alkali metal salts such as, for example, sodium or potassium salts, alkaline earth salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates ,
  • compounds which are preferably present as EGFR inhibitors for use selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofluorate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Preferred dopamine agonists are compounds selected from the group consisting of bromocriptine, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexole, roxindole, ropinirole, talipexole, terguride and viozane, optionally in the form of their racemates, enantiomers , Diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,
  • Hl-antihistamines here preferably compounds are used, which are selected from the group consisting of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetinden, clemastine, bamipine, Cexchlorpheniramin, pheniramine, doxylamine, chlorphenoxamine , Dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclocine, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, tartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • substance formulations or substance mixtures all inhalable compounds are used, such as e.g. also inhalable macromolecules, as disclosed in EP 1 003 478.
  • substances, substance formulations or substance mixtures are used for the treatment of respiratory diseases, which are used in the inhalation area.
  • the compound may be derived from the group of derivatives of ergot alkaloids, triptans, CGRP inhibitors, phosphodiesterase V inhibitors, optionally in the form of their racemates, enantiomers or diastereomers, optionally in the form of their pharmacologically acceptable acid addition salts, their solvates and / or or hydrates.
  • a device for gassing and / or drying the capsule body and capsule caps is arranged directly before the filling of one of the two capsule halves. This is followed by fumigation and / or drying of the capsule body and capsule caps, their filling and the closing of the capsules by latching the capsule body with the capsule caps immediately after one another.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Basic Packing Technique (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

L'invention concerne un procédé utilisé pour remplir des gélules avec une formulation de principe actif pharmaceutique, chaque gélule se composant de deux parties de gélule (un corps de gélule et un capuchon de gélule). Les deux parties de gélule sont assemblées par emboîtement télescopique, sans blocage mutuel préalable à l'état non rempli, uniquement après remplissage d'une partie de gélule avec une formulation de principe actif pharmaceutique.
EP09708924A 2008-02-08 2009-02-07 Procédé et dispositif pour remplir des gélules Withdrawn EP2244686A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09708924A EP2244686A1 (fr) 2008-02-08 2009-02-07 Procédé et dispositif pour remplir des gélules

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08151224 2008-02-08
PCT/EP2009/000863 WO2009098083A1 (fr) 2008-02-08 2009-02-07 Procédé et dispositif pour remplir des gélules
EP09708924A EP2244686A1 (fr) 2008-02-08 2009-02-07 Procédé et dispositif pour remplir des gélules

Publications (1)

Publication Number Publication Date
EP2244686A1 true EP2244686A1 (fr) 2010-11-03

Family

ID=40679384

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09708924A Withdrawn EP2244686A1 (fr) 2008-02-08 2009-02-07 Procédé et dispositif pour remplir des gélules

Country Status (5)

Country Link
US (1) US20100327476A1 (fr)
EP (1) EP2244686A1 (fr)
JP (1) JP2011512175A (fr)
CA (1) CA2714178A1 (fr)
WO (1) WO2009098083A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101829022B (zh) * 2010-05-04 2013-01-23 浙江飞云科技有限公司 高产型胶囊充填机
EP3651721B1 (fr) * 2017-07-10 2024-09-04 Gel Cap Technologies, LLC Capsule a double forme posologique pour libération et procédés, dispositifs et systèmes pour la produire

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2314527A (en) * 1940-07-06 1943-03-23 Atlantic Coast Fisheries Co Method of making sealed capsules
GB818365A (en) * 1955-06-16 1959-08-12 Scherer Corp R P Improvements in or relating to method of making capsules and capsules resulting fromsaid method
GB1054977A (fr) * 1964-01-20
US3552095A (en) * 1968-04-18 1971-01-05 Lilly Co Eli Manual capsule filling apparatus
US5204114A (en) * 1992-03-30 1993-04-20 Health Maintenance Programs, Inc. Methods of manufacturing high dosage glutathione the tablets and capsules produced thereby
US5714007A (en) * 1995-06-06 1998-02-03 David Sarnoff Research Center, Inc. Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate
DE10126924A1 (de) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
ES2413488T3 (es) * 2002-07-05 2013-07-16 Qualicaps Co., Ltd. Aparato de llenado y sellado de cápsulas
JP2004338806A (ja) * 2003-04-25 2004-12-02 Takeda Chem Ind Ltd 粉末充填装置および粉末充填方法
DE102005022862A1 (de) * 2005-05-18 2006-12-14 Airsec S.A.S Kapseln für Inhalatoren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009098083A1 *

Also Published As

Publication number Publication date
US20100327476A1 (en) 2010-12-30
WO2009098083A1 (fr) 2009-08-13
CA2714178A1 (fr) 2009-08-13
JP2011512175A (ja) 2011-04-21

Similar Documents

Publication Publication Date Title
EP2004263B1 (fr) Dispositif d'émission de médicaments et magasins à médicaments
EP2656867B1 (fr) Embouchure pour un inhalateur
EP2066382B1 (fr) Doseur à piston
EP2254630A1 (fr) Inhalateurs de poudre
EP1948274B1 (fr) Aiguille pour percer des capsules de poudre pour l'inhalation
EP2007459A1 (fr) Inhalateur
EP2007458A1 (fr) Inhalateur
EP2007457A1 (fr) Inhalateur
EP2023990A1 (fr) Adaptateur avec raccord pour pulvérisateur
EP2007349B1 (fr) Formulations de suspensions pour aérosols utilisant du tg 227 ea ou du tg 134 a comme propulseur
EP2066380A2 (fr) Inhalateur
EP2001601B1 (fr) Aérosols de dosage pour l'administration de préparations pharmaceutiques
EP2370053A1 (fr) Nouveaux médicaments sous forme de poudre cristalline à inhaler
EP1942968A1 (fr) Inhalateur avec embout ayant une fonction de protection microbiologique
EP2170730A1 (fr) Nouvel agent pharmaceutique poudreux contenant du tiotropium et du salmétérol ainsi que du lactose en tant qu'agent auxiliaire
EP2004261B1 (fr) Dispositif de distribution de médicaments
EP2244686A1 (fr) Procédé et dispositif pour remplir des gélules
EP2001536A1 (fr) Emballage pour inhalateur de poudre multidose avec proprietes optimisees de purge
EP1942867A2 (fr) Absorption du gaz propulseur d'aerosols-doseurs pourvus d'emballages
DE102007052871A1 (de) Kapsel zur Aufnahme von pharmazeutischen Wirkstoffformulierungen
WO2007118857A1 (fr) Capsule en métal en deux parties, destinée à contenir des préparations pharmaceutiques pour inhalateurs à poudre
EP2198972A1 (fr) Réservoir et gicleur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101105